Slide
Redefining the global vaccine landscape with a transformative repRNA vaccine platform

HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.

Slide
Redefining the global vaccine landscape with a transformative repRNA vaccine platform

HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.

Slide
Redefining the global vaccine landscape with a transformative repRNA vaccine platform

HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.

HDT Bio’s self-replicating RNA (repRNA) vaccines harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.

The AMPLIFY vaccine platform — The next generation of RNA vaccines

HDT’s RNA vaccine platform combines its self-amplifying RNA (“repRNA”) and LION™ technology to provide increased potency compared to traditional mRNA vaccines.

Latest News